ABBV-744 in clinical trials for non-small cell lung cancer (NSCLC) Options
The present work examined the potential of employing ARV-825 and ABBV-744 to increase the effectiveness of tamoxifen or fulvestrant in addition palbociclib. ARV-825 was effective in both p53 wild-sort (WT) breast tumor cells and in cells lacking purposeful p53 possibly alone or in combination with tamoxifen, although the effectiveness of ABBV-744 w